CAUSES — Ranked by Prevalence in Mumbai Context
| Category |
Key Drivers |
Mumbai-Specific Note |
|---|
| Metabolic (MASLD) |
Insulin resistance, obesity, T2DM, dyslipidemia, hypertension |
Thin-fat phenotype: normal BMI but high visceral fat — do not be falsely reassured by BMI |
| Alcohol (ALD) |
Chronic excess → steatosis, steatohepatitis |
Significant underreporting; always take AUDIT-C; CAGE scores |
| Dietary |
High refined carbs (maida, white rice, sugar), fructose (fruit juices, packaged foods), trans fats |
Vada pav, misal, bakery products = high glycemic + refined fat load |
| Thyroid dysfunction |
Hypothyroidism → impaired lipolysis |
Often subclinical; TSH must be checked |
| PCOS |
Hyperinsulinism → hepatic lipogenesis |
Underdiagnosed in young women presenting with fatty liver |
| Drugs/Toxins |
Steroids, tamoxifen, valproate, amiodarone, methotrexate |
Ayurvedic/herbal supplements = significant hepatotoxic risk; ask specifically |
| Rapid weight loss / malnutrition |
Paradoxical steatosis |
Post-bariatric or crash-diet patients |
| Genetic |
PNPLA3, TM6SF2 variants |
South Asians at higher fibrotic risk at lower metabolic burden |
STAGING FIRST — Management Depends On It
Before managing, stage the disease:
- FIB-4 score (age × AST / platelets × √ALT) — free, validated, first-line
- Fibroscan (VCTE) — widely available in Mumbai (Lilavati, Kokilaben, Bombay Hospital, multiple GI centers); CAP score for steatosis, kPa for fibrosis
- MRI-PDFF — gold standard for steatosis quantification; available at tertiary centers
- Biopsy if non-invasive tests are discordant or fibrosis stage unclear
MANAGEMENT — Evidence-Based, Mumbai-Actionable
1. Weight Loss (The Most Powerful Lever)
- 7–10% body weight loss → significant steatosis reduction
- >10% → histological MASH resolution and fibrosis regression
- This is not a soft recommendation — it is the single most evidence-supported intervention
- In Mumbai context: structured programs at centers like Bombay Hospital, Nanavati, or SRCC; avoid crash diets (worsen steatosis acutely)
2. Dietary Remodeling (Mumbai-Specific)
| Replace |
With |
|---|
| Maida rotis, white rice |
Jowar, bajra, whole wheat rotis |
| Packaged fruit juices |
Whole fruits (fiber intact) |
| Refined seed oils (soybean, sunflower) |
Cold-pressed groundnut, mustard, limited coconut |
| Late-night heavy meals |
Early dinner (<7:30 PM) |
| Sweetened chai × 4–6/day |
Limit to 1–2; avoid sugar |
- Mediterranean-style diet has the strongest evidence for MASLD — adaptable to Indian vegetarian context
- Fructose restriction is critical; most patients underestimate juice/packaged food fructose load
3. Physical Activity
- 150 min/week moderate aerobic minimum
- Resistance training independently reduces hepatic fat beyond aerobic exercise alone — underutilized in Indian patients
- Brisk walking in Mumbai: practical, free, evidence-backed
4. Pharmacotherapy (Available in India)
| Drug |
Evidence |
Role |
|---|
| Vitamin E (800 IU/day) |
Moderate; PIVENS trial |
Non-diabetic MASH; concerns about long-term use and prostate ca risk in men |
| Pioglitazone |
Strong for T2DM + MASH; NASH CRN data |
Use if diabetic/pre-diabetic; weight gain side effect |
| GLP-1 agonists (semaglutide, liraglutide) |
Strong weight loss + liver fat reduction; LEAN trial, STEP trials |
Increasingly used; semaglutide available in India; ESSENCE trial for MASH ongoing |
| Statins |
Safe in MASLD; cardioprotective |
Do NOT withhold for mild transaminase elevation — common error |
| Resmetirom (Rezdiffra) |
FDA-approved March 2024 for MASH + F2/F3 fibrosis |
Not yet approved in India — verify CDSCO; monitor |
| SGLT2 inhibitors |
Emerging data; hepatic fat reduction |
Use if T2DM present; empagliflozin/dapagliflozin available |
5. Alcohol
- In ALD: complete abstinence is non-negotiable
- In MASLD: even moderate alcohol accelerates fibrosis — advise elimination, not reduction
6. Address Comorbidities Aggressively
- T2DM: optimize glycemic control (HbA1c target <7%)
- Dyslipidemia: statins are safe and indicated
- Hypertension: control to <130/80
- Hypothyroidism: treat to normal TSH
- PCOS: metformin + lifestyle
7. Herbal/Ayurvedic Supplement Review
- Critical and often missed in Mumbai patients
- Multiple supplements (kava, green tea extract, certain churnas) are hepatotoxic
- Take a full supplement history; stop anything unverified
Monitoring Protocol
| Parameter |
Frequency |
|---|
| LFTs, lipids, FBS/HbA1c |
Every 6 months |
| FIB-4 recalculation |
Annually |
| Fibroscan |
Every 1–2 years if no fibrosis; annually if F1–F2 |
| HCC surveillance (USG + AFP) |
Every 6 months if cirrhotic |
Red Flags → Refer to Hepatologist Immediately
- FIB-4 >2.67 (high fibrosis probability)
- Fibroscan >8 kPa
- Thrombocytopenia, splenomegaly, low albumin
- Rapidly rising bilirubin or coagulopathy
- Any suspicion of HCC
